Amol Akhade/hiranandanihospital.org
May 30, 2025, 22:44
Amol Akhade: Matterhorn Trial: ASCO 2025 Spotlight
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on X:
Matterhorn Trial – ASCO 2025 Spotlight
Can perioperative immunotherapy change outcomes in resectable gastric/GEJ cancer?
At GI25, MATTERHORN (Durvalumab + FLOT) showed:
pCR: 19% vs 7%
T0: 23% vs 11%
N0: 52% vs 36%
As Per press release: EFS is statistically significant and clinically meaningful.
But KN585 – PCR BENIFIT but no EFS gain
Why MATTERHORN may succeed where KEYNOTE-585 fell short:
100% got triplet chemo (vs 20% in KN585)
60% completed peri-op FLOT (vs 48 % )
Now your turn- put your brain and give me your best guess for the EFS outcome?
HR and Gain in median EFS
See the POLL and VoteSo for matterhorn , we are not so sure about magnitude of benifit?
34 % around feel that magnitude of EFS gain will be 8 to 10 months over FlOT alone .”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56